Jeonjinbio Co., Ltd.

KOSDAQ:A110020 Stock Report

Market Cap: ₩16.5b

Jeonjinbio Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Jeonjinbio.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Chemicals earnings growth66.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Nov 21

Returns At Jeonjinbio (KOSDAQ:110020) Are On The Way Up

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Analysis Article • Sep 03

The Price Is Right For Jeonjinbio Co., Ltd. (KOSDAQ:110020) Even After Diving 28%

Unfortunately for some shareholders, the Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) share price has dived 28% in the last...
Analysis Article • Jul 24

Returns On Capital Are Showing Encouraging Signs At Jeonjinbio (KOSDAQ:110020)

There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...
Analysis Article • Mar 14

We Think Jeonjinbio's (KOSDAQ:110020) Robust Earnings Are Conservative

The subdued stock price reaction suggests that Jeonjinbio Co., Ltd.'s ( KOSDAQ:110020 ) strong earnings didn't offer...
Analysis Article • Jan 07

Jeonjinbio Co., Ltd.'s (KOSDAQ:110020) Price In Tune With Revenues

When close to half the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S") below 0.6x...
Analysis Article • Oct 25

There's Been No Shortage Of Growth Recently For Jeonjinbio's (KOSDAQ:110020) Returns On Capital

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
Analysis Article • Jun 07

With A 38% Price Drop For Jeonjinbio Co., Ltd. (KOSDAQ:110020) You'll Still Get What You Pay For

The Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) share price has fared very poorly over the last month, falling by a...
Analysis Article • Apr 03

Shareholders Should Be Pleased With Jeonjinbio Co., Ltd.'s (KOSDAQ:110020) Price

Jeonjinbio Co., Ltd.'s ( KOSDAQ:110020 ) price-to-sales (or "P/S") ratio of 3.7x may look like a poor investment...
Analysis Article • Apr 13

Is Jeonjinbio (KOSDAQ:110020) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Feb 19

If You Had Bought Jeonjinbio (KOSDAQ:110020) Shares A Year Ago You'd Have Earned 101% Returns

While Jeonjinbio Co., Ltd. ( KOSDAQ:110020 ) shareholders are probably generally happy, the stock hasn't had...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jeonjinbio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A110020 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202614,421171,0291,699N/A
12/31/202513,694-196-308483N/A
9/30/202514,654728-358505N/A
6/30/202515,4519561,2542,108N/A
3/31/202517,0224,2451,7191,966N/A
12/31/202419,2734,3462,6113,005N/A
9/30/202419,9599782,1902,877N/A
6/30/202419,142-2016411,392N/A
3/31/202417,686-5,550-538239N/A
12/31/202315,681-6,440-972-301N/A
9/30/202313,204-4,327-2,280-1,263N/A
6/30/202310,893-4,905-3,590-2,355N/A
3/31/20239,055-2,999-4,441-2,518N/A
12/31/20227,794-3,113-5,839-3,710N/A
9/30/20225,899-2,504-5,214-3,811N/A
6/30/20224,557-2,228-4,631-3,509N/A
3/31/20223,457-2,462-2,828-2,363N/A
12/31/20213,214-2,108-4,318-2,385N/A
9/30/20213,496-3,609-5,978-2,665N/A
6/30/20213,796-3,275-7,682-3,215N/A
3/31/20213,910-3,882-8,382-3,369N/A
12/31/20203,867-3,418-8,147-2,310N/A
9/30/20204,732-1,604-6,438-1,637N/A
6/30/20204,643-1,648-4,798-926N/A
3/31/20204,426-1,330-3,836-501N/A
12/31/20193,949-1,462N/A-1,299N/A
9/30/20192,230-3,437N/A-2,330N/A
6/30/20191,357-3,579N/A-2,721N/A
3/31/20191,243-3,495N/A-2,908N/A
12/31/20181,384-3,399N/A-2,161N/A
9/30/20182,216-3,610N/A-1,133N/A
6/30/20182,392-3,366N/A-846N/A
3/31/20182,792-3,130N/A-586N/A
12/31/20173,136-3,041N/A-413N/A
9/30/20172,645-2,626N/A-429N/A
6/30/20173,106-3,325N/A-241N/A
3/31/20172,895-3,697N/A166N/A
12/31/20164,809-3,074N/A-182N/A
12/31/20152,018-2,931N/A-1,953N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A110020's forecast earnings growth is above the savings rate (3.1%).

Earnings vs Market: Insufficient data to determine if A110020's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A110020's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A110020's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A110020's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A110020's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 11:15
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jeonjinbio Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.